Takeda Am Drug Patent Portfolio

Takeda Am owns 1 orange book drug protected by 6 US patents Given below is the list of Takeda Am's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10030061 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
Active
US10442846 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
Active
US10501515 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
Active
US11807674 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
Active
US12269856 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
Active
US9822157 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
Active


Takeda Am's Family Patents


Family Patents



Takeda Am Drug List

Given below is the complete list of Takeda Am's drugs and the patents protecting them.


1. Mimrylo

Mimrylo is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10030061 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
(7 years from now)
Active
US10442846 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
(7 years from now)
Active
US10501515 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
(7 years from now)
Active
US11807674 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
(7 years from now)
Active
US12269856 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
(7 years from now)
Active
US9822157 Hepcidin Analogues And Uses Thereof 17 Mar, 2034
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mimrylo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List